Stockwinners Market Radar for March 28, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:00 EDT Equus Total Return reports net assets of $35.2M as of December 31 - Equus Total Return reported net assets as of December 31, 2022, of $35.2M. Net asset value per share decreased to $2.61 as of December 31, 2022, from $2.68 as of September 30, 2022.

17:54 EDT Northrop Grumman awarded $128.46M Air Force contract modification - Northrop Grumman has been awarded an $128.46M firm-fixed-price modification to a contract for Active Electronically Scanned Array radars of Air Force F-16 aircraft. This modification is for the exercise of options to include 48 radars, 4 initial spare kits, and 2 readiness spares kits. Work will be performed in Linthicum Heights, Maryland, and is expected to be completed May 30, 2031. The total cumulative face value of the contract is $1.48B. FY21 procurement funds in the amount of $457,758.00; FY22 aircraft procurement funds in the amount of $55.14M and FY23 procurement funds in the amount of $72.85M are being obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:30 EDT Raytheon Technologies awarded $1.23B Army contract - Raytheon was awarded a $1.23B firm-fixed-price contract for Patriot Missile System fire units. Bids were solicited via the internet with two received. Work has an estimated completion date of December 31, 2032. FY23 Foreign Military Sales funds in the amount of $1.23B were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:24 EDT N-able to replace iStar in S&P 600 at open on 4/3 - Safehold (SAFE) is acquiring iStar (STAR) effective prior to the opening of trading on Friday, March 31. Immediately prior to its acquisition by Safehold, iStar will distribute shares in Star Holdings (STHO). Star Holdings is not eligible for the S&P SmallCap 600 following the spin-off transaction as it is not representative of the small-cap market space.

17:15 EDT Google teams with AI firm Replit to aid generative AI for software development - Leading cloud software development platform Replit announced a new strategic partnership with Google Cloud. Under the new partnership, Replit developers will get access to Google Cloud infrastructure, services, and foundation models via Ghostwriter, Replit's software development AI, while Google Cloud and Workspace developers will get access to Replit's collaborative code editing platform. The collaboration will accelerate the creation of generative AI applications and underscores Google Cloud's commitment to nurturing the most open ecosystem for generative AI..For developers using Replit's Ghostwriter coding AI, more than 30% of their code is generated by Ghostwriter. The newest LLM chat apps can generate code for full programs with simple natural language prompts, enabling the creation of full websites with no coding experience in minutes. But even powerful LLMs can't run code themselves. Standalone chat LLMs do not have a project's context. They require developers to copy and paste code from where they work to the chat app... Until LLMs are brought into the integrated development environment itself, IDE , we aren't yet at the future that Replit CEO Amjad Masad has laid out, where AI will help: Make non-developers into developers, turning natural language to code...Turn software engineers to hyper-productive "10X engineers"...Replit's cloud infrastructure and AI products like Ghostwriter make it one of the fastest places to go from idea to deployed software application. Through this new partnership with Google Cloud, developers using Replit will have global access to Google Cloud infrastructure and Google's foundation models on Vertex AI. The collaboration aims to support Google Cloud's goal of enabling companies to accelerate their development process using AI. Other companies that have similar products or services include Microsoft (MSFT) and Amazon (AMZN).

17:01 EDT FleetCor appoints Tom Panther as CFO - FLEETCOR Technologies announced the appointment of Tom Panther as CFO, effective May 12. Prior to joining FLEETCOR, Tom served as the CFO at EVO Payments prior to its acquisition by Global Payments. Tom was instrumental in EVO delivering strong revenue growth and significant margin expansion, as well as executing a number of key initiatives, including international M&A, debt and capital financings, and serving as a key advisor to the Board regarding the recent sale of EVO. Prior to joining EVO, Tom worked at SunTrust Banks, Inc. for nearly 20 years serving in numerous leadership roles including Chief Accounting Officer, Corporate Controller, SVP of Corporate Finance, and Head of Capital Planning & Analysis. He began his career at Arthur Andersen, is a certified public accountant, and earned his bachelor's degree from the University of Richmond.

16:51 EDT Micron says now expects overall headcount reduction to approach 15% - Says has made additional reductions to fiscal 2023 capex plan and now expects to invest approximately $7B, down more than 40% from last year, with wafer fab equipment, or WFE, down more than 50%. Says in fiscal 2024, expects WFE to fall further. Says further reduced DRAM and NAND wafer starts, which are now down by approximately 25%. Says for calendar 2023 now expects Micron's year-on-year bit supply growth to be meaningfully negative for DRAM. Says also expects to produce fewer NAND bits in calendar 2023 than in calendar 2022. Says made further reductions to operating expenses beyond the executive salary cuts and suspension of Micron's fiscal 2023 bonuses companywide. Says now expect overall headcount reduction to approach 15%.

16:46 EDT Micron says further reducing supply - Says semiconductor memory and storage industry is facing worst downturn in the last 13 years, with an exceptionally weak pricing environment that is significantly impacting financial performance. Says has taken substantial supply reduction and austerity measures, including executing a companywide reduction in force. Says expects calendar 2023 smartphone unit volume to be down slightly year over year. Says expectations for calendar 2023 industry bit demand growth have moderated to approximately 5% in DRAM and low-teens percentage range in NAND. Says expects that improving customer inventories will support sequential bit demand growth for DRAM and NAND through the calendar year. Says China's reopening is also a positive factor for calendar 2023 bit demand. Comments taken from Q2 earnings conference call.

16:38 EDT Lululemon jumps 9% to $348.97 after Q4 results, FY23 guidance beat estimates

16:29 EDT ServisFirst Bank expands Correspondent Banking Division into Texas - ServisFirst Bank, a subsidiary of ServisFirst Bancshares, announced the expansion of the Correspondent Banking Division into Texas. Founded in 2011, ServisFirst Bank's Correspondent Banking Division currently operates in 27 states for 344 correspondent bank customers. Veteran banker, Don Dickerson will serve as Senior Vice President, Correspondent Banking for the Texas region. "We are excited to expand our Correspondent Banking Division into Texas to offer a program that will help banks offer quality products and solutions to their customers," states Rodney Rushing, ServisFirst Bank Executive Vice President and Chief Operating Officer. "With Don's leadership and wide-ranging banking experience, ServisFirst will continue to provide exceptional service across the United States."

16:22 EDT Turtle Beach adopts limited duration stockholder rights plan - Turtle Beach Corporation announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is April 10, 2023. The adoption of the Rights Plan is intended to enable all stockholders to realize the full potential value of their investment in the Company and protect the Company and its stockholders from the actions of third parties that the Board determines are not in the best interests of the Company and its stockholders. In addition, the Rights Plan provides the Board with time to make informed, deliberate decisions that are in the best long-term interests of the Company and its stockholders. The Rights Plan will expire on March 28, 2024.

16:12 EDT The Standard to acquire Life & Disability business from Elevance Health - StanCorp Financial Group and Elevance Health announced a definitive agreement under which The Standard will acquire the Life & Disability business from Elevance Health and enter into a product distribution partnership. The Standard and Elevance Health are leading benefits providers with deep expertise in group benefits administration and a shared commitment to customer service. The Standard, a top group life, disability and ancillary benefit provider, was founded in 1906 and sold its first employee benefits policy in 1951, a case that remains in force today. Elevance Health is an industry leader in health solutions that serves customers through a diverse portfolio of medical, digital, pharmacy, behavioral, clinical, and complex care solutions. Its Life & Disability unit is a respected provider of life, disability and related employee benefits.

16:06 EDT Blueprint Medicines: FDA lifts partial clinical hold on Phase 1/2 VELA trial - Blueprint Medicines announced that the U.S. FDA has lifted a partial clinical hold on the Phase 1/2 VELA trial of BLU-222. On February 10, 2023, Blueprint Medicines announced the FDA placed a partial clinical hold on the VELA trial due to reported visual adverse events, consisting of transient, reversible episodes of light sensitivity and blurred vision, observed in a limited number of patients. Patients already enrolled in the trial have continued receiving study drug. The partial clinical hold is lifted as of March 28, and Blueprint Medicines is working with trial sites to reinitiate patient enrollment. "With a focus on patient safety, we have worked diligently with the FDA over the last several weeks to resolve the partial clinical hold by updating adverse event monitoring and management procedures. We will now collaborate closely with investigators to resume patient enrollment," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "We are confident in the potential of BLU-222 to improve outcomes in patients with cancers vulnerable to CDK2 inhibition, and we look forward to presenting initial dose escalation data from the VELA trial in the second quarter of 2023."

16:00 EDT BlackSky says it successfully commissioned two new satellites - BlackSky Technology said it successfully commissioned two new satellites that began revenue-generating commercial operations within 18 hours of "The Beat Goes On" launch mission. "BlackSky has more than doubled our on-orbit capacity in the last 18 months, with enough capacity to support growth over the next two years," said Nick Merski, BlackSky chief operating officer. "Our flexible architecture gives us the ability to realize incremental benefits quickly as we add ever-advancing, multi-generational capability to our constellation."

15:02 EDT Weave announces expanded partnership with Stripe - Weave and Stripe announced a multi-year agreement to process payments on Stripe Connect for Weave's 27,000+ specialty healthcare customers across the U.S. Weave CEO Brett White said: "Our renewed relationship with Stripe as our strategic partner, combined with Weave's award-winning customer communication and engagement technology, is helping offices power convenient and modern payment experiences that their patients want." The companies added: "As part of the expanded partnership renewal, Weave has added Stripe Capital, an embedded finance option for business owners, to its all-in-one platform. Stripe Capital provides access to fast, flexible financing so small business owners can manage cash flows and invest in growth. Weave will leverage additional Stripe features later this year as it expands its Payments offering for existing and new customers, helping small businesses be even more successful in engaging their patients, collecting balances, and meeting the growing demand for digital payment options like Text to Pay and mobile wallets like Apple Pay and Google Pay."

13:53 EDT Lucid Group down 6% to $7.64 following report of layoffs

13:29 EDT Vanda announces win in jet lag FOIA litigation against FDA - Vanda Pharmaceuticals announced a win in its jet lag FOIA litigation against the FDA. On March 27, a federal court granted final judgment in favor of Vanda in its Freedom of Information Act, or "FOIA," case requesting records created by the Food and Drug Administration during its review of Vanda's application seeking approval of a new use for its drug, Hetlioz. "Vanda filed the lawsuit, Vanda Pharmaceuticals, Inc., v. Food and Drug Administration, case no. 1:22-cv-00938, in the United States District Court for the District of Columbia in April 2022 to compel the FDA to produce, as required by FOIA, certain records relating to its denial of Vanda's supplemental New Drug Application for HETLIOZ in the treatment of jet lag disorder. Vanda had repeatedly attempted to obtain these records from the FDA pursuant to a FOIA request it submitted in December 2019, but the FDA had refused to disclose those records, invoking the deliberative process exemption under FOIA. The court rejected the FDA's claim that it would suffer 'foreseeable harm' if it disclosed to Vanda its reviews relating to Vanda's sNDA. In particular, the court held that in the context of this case, contrary to the FDA's assertion, '[d]isclosure cannot chill' the 'deliberations' of agency staff... As part of its ruling, the federal court issued a final and appealable order in Vanda's favor, which also denied the FDA's cross-motion for summary judgment," according to the company. Dr. Mihael H. Polymeropoulos, Vanda's President, CEO and Chairman of the Board, said: "In order to facilitate the development of promising new therapeutics for unmet patient needs, it is crucial that the FDA work collaboratively with drug innovators. The court's ruling today constitutes an important step to ensure appropriate transparency at the FDA, which is essential to scientific advancement in the service of public health."

12:55 EDT China Online Education trading halted, volatility trading pause

12:00 EDT Cian submits appeal to NYSE delisting determination - Cian announces that, on March 28, 2023, the Company submitted a written request for a review by a Committee of the Board of Directors of the New York Stock Exchange of the determination of the staff of the New York Stock Exchange Regulation to delist the Company's American depositary shares, each representing one ordinary share of the Company, from New York Stock Exchange. As previously announced, the Company received a written notice of such determination by the Staff on March 15, 2023. Pursuant to Section 804.00 of the NYSE Listed Company Manual, the review by the Committee will generally be scheduled for a date that is at least 25 days from the date of the request for review. The delisting of the Company's securities will be stayed pending the conclusion of the review process, while the trading suspension that was implemented on February 28, 2022 will remain in effect. There can be no assurance that the Committee will grant the Company's request for continued listing on the NYSE. The company said, "We believe that the Company has been and remains in full compliance with all applicable reporting obligations and qualitative and quantitative listing criteria of the NYSE and has met all additional requests for disclosure by the NYSE since the suspension of trading on February 28, 2022." The trading of the Company's ADSs on the Moscow Exchange is unaffected and continues as usual.

12:00 EDT Turkcell falls -6.3% - Turkcell is down -6.3%, or -28c to $4.15.

12:00 EDT IHS Holding rises 18.3% - IHS Holding is up 18.3%, or $1.30 to $8.40.

12:00 EDT Oscar Health rises 79.9% - Oscar Health is up 79.9%, or $2.87 to $6.46.

11:44 EDT Puyi Inc (ADR) trading halted, volatility trading pause

11:15 EDT Harmony Biosciences 'disagrees' with Scorpion Capital's 'assertions' - In a statement emailed to The Fly, a spokesperson for Harmony Biosciences said the company was aware of Scorpion Capital's report and that it disagrees with their assertions. "We are aware of this report from an activist investor and disagree with their assertions. We remain committed to helping those who live with devasting rare diseases, and our science has been subject to peer review and received global regulatory approval. We'll continue to innovate and develop safe and effective medications for those in need. With regards to a Citizen Petition, we have not seen anything filed publicly at this time."

10:28 EDT Guardion Health Sciences Inc trading resumes

10:09 EDT Biomea Fusion trading resumes

10:04 EDT Biomea Fusion trading halted, volatility trading pause

10:00 EDT Turkcell falls -5.0% - Turkcell is down -5.0%, or -22c to $4.21.

10:00 EDT McCormick rises 12.9% - McCormick is up 12.9%, or $9.57 to $83.63.

10:00 EDT Oscar Health rises 53.8% - Oscar Health is up 53.8%, or $1.93 to $5.52.

09:47 EDT StarTek falls -4.8% - StarTek is down -4.8%, or -19c to $3.81.

09:47 EDT Alibaba rises 12.4% - Alibaba is up 12.4%, or $10.67 to $96.79.

09:47 EDT Oscar Health rises 40.8% - Oscar Health is up 40.8%, or $1.47 to $5.05.

09:42 EDT ARS Pharmaceuticals announces FDA Advisory Committee meeting for neffy - ARS Pharmaceuticals announced that the U.S. Food and Drug Administration has scheduled a Division of Pulmonology, Allergy and Critical Care Advisory Committee meeting on May 11, 2023 to review the new drug application for neffy. The FDA stated the following regarding an Advisory Committee in its official pre-NDA meeting minutes received by ARS: An Advisory Committee is an important aspect of the review given the new route of administration for an emergency use product that has clinical efficacy trial feasibility issues. Additional experts with knowledge in systemic allergic reactions and anaphylaxis will be invited to participate in the Advisory Committee. The FDA would not be planning to bring ARS's application to an Advisory Committee if they did not feel the PK/PD provided by ARS had the potential for approval. The Company's NDA submission for neffy was accepted for review by the FDA with a Prescription Drug User Fee Act target action date anticipated in mid-2023.

09:33 EDT Nevada reports February statewide gaming win up 11.15% to $1.24B - Nevada reports February Las Vegas Strip gaming win up 18.92% to $712.46M versus last year. Publicly traded companies in the gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:26 EDT Antelope Enterprise Holdings regains compliance with Nasdaq listing rules - Antelope Enterprise Holdings, the majority owner and operator of KylinCloud, a leading livestreaming social ecommerce platform with 300,000+ anchors and influencers in China, announced that on March 27, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market confirming the Company has regained compliance with NASDAQ's minimum bid price requirement under Listing Rule 5550. The Company regained compliance with NASDAQ's requirements when the closing bid price for the Company's Class A ordinary shares were at or above $1.00 for 10 consecutive business days and the matter is now closed.

09:21 EDT Nexa Resources says Cerro Lindo resumes operations - Nexa Resources announced that Cerro Lindo has resumed its operations. The road access has been restored. However, some drainage systems are still being repaired. The plant is currently operating according to our production plan, 17ktpd, while the underground mine dewatering process is progressing as planned and is expected to be completed within 15 days. Cerro Lindo produces approximately 233t of zinc per day. The 1Q23 production loss is expected to be recovered in the upcoming quarters. The 2023 guidance remains unchanged as of the date of this press release.

09:19 EDT Upwork appoints Erica Gessert as CFO - Upwork (UPWK) announced that Erica Gessert will join the company as chief financial officer CFO, effective April 25. Gessert joins from PayPal (PYPL), where she held a number of senior leadership roles since 2015, most recently including chief transformation officer reporting to the CEO, and senior vice president of finance & analytics...Prior to PayPal, from 2009 to 2014, Gessert served in a variety of roles for Sprint Corporation, including VP of finance for Sprint Postpaid marketing and chief financial officer for the Sprint Prepaid business unit, as well as director of investor relations. She previously served as head of investor relations for Virgin Mobile USA from 2007 to 2009.

09:16 EDT Kontrol selected by Fortune 100 customer for energy monitoring, optimization - Kontrol Technologies has been selected by a Fortune 100 Customer for energy monitoring and facility optimization spanning 1.6 Million square feet of built environment. Kontrol will provide its technology solution for real-time energy monitoring and facility optimization, which includes initial design, implementation, and ongoing monthly recurring revenues. "We are very pleased to be selected by such a significant Customer for energy monitoring and facility optimization," said, Paul Ghezzi, CEO of Kontrol Technologies. "As we deliver our technology platform to reduce energy costs and optimize performance in real-time, we will seek to scale with this new Customer into additional potential building opportunities."

09:15 EDT Pressure BioSciences' PBI Agrochem ships, bills initial $130,000 order - Pressure BioSciences and its wholly-owned subsidiary PBI Agrochem announced it has shipped and billed an initial $130,000 order for its potent, environmentally-responsible nematode control product. The Company also announced that its newly-developed sales channel has provided confidence that an ongoing and growing pipeline of demand is expected to follow for this and other eco-friendly products in the Company's portfolio.

09:11 EDT Aware brings AwareID to AWS Marketplace - Aware announced it is working with SoftwareONE and AWS to prepare AwareID for availability on AWS Marketplace. As part of this program, Aware will be working with SoftwareONE to optimize AwareID's product efficiency in the cloud and on AWS's Marketplace. SoftwareONE accepted Aware into its development program where AWS fully funds projects specific to modernizing technology offerings and preparing them for listing in AWS Marketplace.

09:11 EDT Evercore selects Behavox to provide AI-driven solution for compliance program - Behavox announced that Evercore has contracted with Behavox for its services. The selection comes after a rigorous process that included a review of multiple vendors, in which Behavox demonstrated the highest capability to meet Evercore's requirements of providing broad and industry-validated risk coverage, the ability to surveil all communication data types within the organization and provide robust management information reporting capabilities. Critical to Evercore's selection of Behavox was also its proven ability to advance its clients' target operating models and implement its solution at speed.

09:10 EDT Pacific Biosciences announces new workflows developed with Corteva - PacBio (PACB) announced new workflows developed with Corteva Agriscience (CTVA) that enable high throughput plant and microbial genome sequencing. This collaboration, which originated at the Advances in Genome Biology and Technology, or AGBT, Agricultural meeting last year, delivers end-to-end workflows that streamline DNA extraction through library preparation, enabling Corteva to sequence thousands of samples annually, as part of their innovative seed and crop protection research and production programs. The initial phase of the collaboration saw the development of scaled DNA extraction, shearing, and library preparation workflows to characterize Corteva's vast collection of crop and microbial samples. These novel workflows were specifically engineered to support cost-effective, ultra-high throughput long-read sequencing, opening new possibilities for studying crop genetics and diversity in a transformative way. The results of this collaboration were announced at the Advances in Genome Biology and Technology

09:09 EDT Pacific Biosciences announces new workflows developed with Corteva - PacBio announced new workflows developed with Corteva Agriscience that enable high throughput plant and microbial genome sequencing. This collaboration, which originated at the Advances in Genome Biology and Technology, or AGBT, Agricultural meeting last year, delivers end-to-end workflows that streamline DNA extraction through library preparation, enabling Corteva to sequence thousands of samples annually, as part of their innovative seed and crop protection research and production programs. The initial phase of the collaboration saw the development of scaled DNA extraction, shearing, and library preparation workflows to characterize Corteva's vast collection of crop and microbial samples. These novel workflows were specifically engineered to support cost-effective, ultra-high throughput long-read sequencing, opening new possibilities for studying crop genetics and diversity in a transformative way. The results of this collaboration were announced at the Advances in Genome Biology and Technology

09:08 EDT Evan Berlin named COO at EverCommerce - EverCommerce that it has appointed Evan Berlin Executive Vice President and Chief Operating Officer. In this expanded role, Evan will be responsible for the operational execution of the company's solution lines of business and will report to EverCommerce's President, Matt Feierstein. "The Board of Directors and I are thrilled to have Evan in this role," said Eric Remer, EverCommerce CEO. "We believe his background, established track record of success and passion for achieving the vision we have set forth will drive growth opportunities for our customers, our employees, and our shareholders." Berlin brings nearly 20 years of experience to this role. Most recently he served as EVP of EverCommerce's solution group operations where he led the company's EverPro, EverHealth and payment solutions. Berlin joined EverCommerce's predecessor company, PaySimple, in 2008. During his long tenure building the company, he has held various management, corporate development and operational leadership roles. Prior to joining EverCommerce, he began his career at CEB, now a division of Gartner. Berlin holds a bachelor's degree in business administration from the University of Colorado Boulder. "It's been a pleasure to have played an integral role in building EverCommerce into the company it is today," said Evan Berlin. "I look forward to furthering our success and growing as a leading service commerce platform."

09:06 EDT Mullen Automotive files lawsuit against Intersection Media Group - Mullen Automotive filed a civil complaint for defamation in the Superior Court of Delaware today alleging that on March 22, 2023, dot.LA published an article on its website authored by David Shultz that contained false and defamatory statements regarding Mullen, including false and defamatory statements regarding the terms of a settlement agreement of a civil action. McDermott Will & Emery LLP, a leading international law firm, has been retained to represent the Company in the lawsuit.

09:05 EDT Giga-tronics reports Q4 bookings exceeding $8M - Giga-tronics, Inc. d/b/a Gresham Worldwide announced its global new business bookings exceeded $8 million for the most recent quarter ending December 31, 2022. Gresham continues to drive new business with increased focus on integrated Radio Frequency filter solutions systems within the defense sector as well as an expanded product offering with technology solutions for medical applications. Ongoing geopolitical military conflict, supply chain turmoil and inflation are expected to drive continued demand from customers for Gresham's product offerings in 2023 and beyond. Increasing defense budgets for electronic technology solutions have created opportunities for Gresham to expand relationships with the U.S. Department of Defense, Global Defense Ministries and Tier One Defense Contractors. For the fiscal year ended 2022, Gresham had a backlog of approximately $30 million, up from $25 million for the prior fiscal year, providing a pathway for stable growth. The recent share exchange between Giga-tronics and Gresham Worldwide expanded both Gresham's customer base and portfolio of solutions. Gresham's management team expects continued global demand for technology solutions to support mission critical applications in defense, medical, transportation and telecommunications in 2023. Gresham continues to drive operational efficiencies post-merger, reducing operating expenses and streamlining manufacturing processes. Gresham is focused on meeting new requirements for existing customers and developing business with new customers to drive bookings and build additional backlog in 2023.

09:03 EDT Applied Industrial Technologies names new General Counsel, Secretary - Applied Industrial Technologies (AIT) announced that Jon Ploetz has joined the Company as Vice President - General Counsel & Secretary. In this role, Ploetz will lead the Company's global legal affairs, governance and compliance activities, ESG efforts, and corporate secretary duties. Ploetz succeeds Fred Bauer who elected to retire effective January 31, 2023, after 30 years of service to the Company. Bauer remained the Company's Secretary throughout the replacement search; his official departure is March 31, 2023. Ploetz joins Applied from Harsco Corporation (HSC) where he served as Vice President, Assistant General Counsel & Assistant Corporate Secretary since 2018, and Assistant General Counsel, Corporate & Securities prior to that.

09:02 EDT Miniso announces plans to expand into three new markets - Miniso has announced its plans to expand operations into three new markets, namely Angola, Trinidad and Tobago, and Latvia. With Panama, the four new partnerships were unveiled during Miniso's Global Partners Summit, held in Guangzhou, China, in March 2023.

09:02 EDT RealReal announces enhancements for seller experience - The RealReal announced significant enhancements for its seller experience. The RealReal has enhanced its consignment service model, now called RealService, which adds a dedicatedConsignor Concierge team to support sellers during every step in the consignment process. In addition to having an assigned Luxury Manager who helps sellers know what, when and how to sell and the team of experts who authenticate, price, and list every item on behalf of the consignor, the Consignor Concierge team will be the designated point-of-contact who will support and assist customers with any questions regarding the process. New product features such as the Resale Insights Center and The Handbag Pricing Estimator today, putting seller education at the forefront - placing deep data and expertise directly into the hands of its consignors. With more than a decade's worth of data from 30M+ items sold to date, the Resale Insights Center will help consignors understand how The RealReal prices each item and powers the Handbag Pricing Estimator, which allows customers to get an estimate of what their handbag is worth prior to consigning.

09:00 EDT Virpax Pharmaceuticals appoints Ruskin to board of directors - Virpax Pharmaceuticals (VRPX) announced that the Company has appointed Barbara Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members. Most recently Dr. Ruskin serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics (SLN)

08:46 EDT iSun wins five new solar projects valued at $5.1M in Vermont - iSun announced that it had secured five contracts covering 6.5 MW and valued at $5.1 million in Vermont, to provide expanded solar energy capabilities at five industrial sites. HIGHLIGHTS: 6.5 MW in contracts expands iSun's already active and completed projects in the Vermont market; $5.1 million in new contracts highlights iSun's momentum in building upon existing customer relationships in 2023; Projects scheduled to begin in spring 2023 and are expected to be completed in 2023 and 2024. "We are excited to start 2023 by securing more new contracts that build upon the accelerated pace of contract wins we generated in the second half of 2022. These new projects with existing customers in Vermont demonstrate the momentum within our industrial division, and we're pleased that execution on these projects will begin this spring," said Jeffrey Peck, Chairman and Chief Executive Officer of iSun. "In 2023, we are focused on execution and efficiency, and we appreciate the trust and confidence of our customers in our ability to help them achieve their goals in alternative energy initiatives. This award demonstrates yet again our strong commitment to accelerating the transition to solar energy for customers in New England."

08:45 EDT Simulations Plus enters new strategic collaboration with SACF - Simulations Plus announced that it established a strategic research collaboration with the Sino-American Cancer Foundation, SACF. This collaboration will leverage Simulations Plus' staff and Artificial Intelligence-driven Drug Design technology in the ADMET Predictor software platform to support the discovery and design of novel inhibitors of methylenetetrahydrofolate dehydrogenase 2, an emerging cancer target. Per the terms of the collaboration, Simulations Plus will develop quantitative structure-activity relationship models for efficacy against MTHFD2, using information from SACF as well as academic and patent literature. The biologists, computational and medicinal chemists in the Early Drug Discovery Services team at Simulations Plus will work with the researchers at SACF to define the multi-objective parameters against which the lead molecule will be optimized. The new AIDD Module in ADMET Predictor will then be employed to generate libraries of virtual compounds that are optimized for potency and other chosen parameters.

08:43 EDT Eterna appoints Jeff Karp to Scientific Advisory Board - Eterna Therapeutics announced the appointment of Jeff Karp, Ph.D. to Eterna's Scientific Advisory Board. Karp is the Distinguished Chair in Clinical Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital and Professor of Anesthesia at Harvard Medical School in Boston.

08:43 EDT Proxy advisors recommend Sabina shareholders vote for B2Gold arrangement - Sabina Gold & Silver Corp. announced that both Institutional Shareholders Services and Glass Lewis & Co. have recommended Sabina shareholders vote FOR the previously announced plan of arrangement with B2Gold Corp. at the Company's upcoming special meeting of shareholders to be held on April 12, 2023.The Meeting will seek shareholder approval for the acquisition of all of the issued and outstanding shares of the Company by B2Gold, with Sabina shareholders receiving 0.3867 of a common share of B2Gold for each Sabina common share held, which represents a premium of 45% to the 20-day VWAP of each of B2Gold and Sabina on the TSX as of February 10, 2023, the last trading day before the announcement of the Arrangement, as well as when compared to the closing price of Sabina on the TSX as of February 2, 2023, the date the non-binding letter of intent was signed. In ISS's view, they found "(t)he transaction makes strategic sense as the combination will combine the attractive development assets and minerals reserves of (Sabina) with the size, scale, human capital, balance sheet, and cash flow generating capabilities of (B2Gold)" and that the Arrangement "will reduce some of the financing and execution risk currently borne by (Sabina) shareholders while providing an 18 percent premium to the unaffected date and (Sabina)'s highest share price since 2021." In conclusion, ISS cited the favourable comparison of the Arrangement to other similar transactions in the past 24 months and the market reaction as further reasons for shareholders to vote FOR the Arrangement. Additionally, according to Laurel Hill Advisory Group, the Company's proxy solicitation advisor, "Glass Lewis saw the strategic rationale for the Arrangement to be "straightforward," while their quantitative analysis found the Arrangement implied a price-to-net asset value of 0.54x, which was in the 84th percentile of trading multiples observed in Glass Lewis' peer set, as well as that the premium to the 30-day volume-weighted average price fell in the 71st percentile of their comparable transaction data set. Taking these factors together, Glass Lewis found that shareholders should vote FOR the Arrangement."

08:40 EDT BIO-key strategically teams with Ethnos IT Solutions expanding Africa reach - BIO-key International announced a strategic partnership with Ethnos IT Solutions to bring innovative IAM solutions to customers across Africa who are looking to enhance their cybersecurity with improved access security and seamless user experiences. Ethnos is Africa's leading cybersecurity and compliance management company. As a Value-Added Reseller, they provide Information Security, Risk Management, Cybersecurity and Compliance Management solutions to small and mid-sized enterprises, corporations, and government institutions across Africa, with a focus on the Banking, Fintech, Telecom, Education, and Oil and Gas sectors. The partnership with Ethnos further strengthens the international presence of BIO-key's IAM and Identity-Bound Biometric solutions. Ethnos joins BIO-key's global Channel Alliance Partner program which makes it easy for partners to develop new recurring revenue streams via BIO-key's full line of solutions, including its award-winning PortalGuard platform. PortalGuard supports multi-factor authentication with unique IBB methods, single sign-on, and self-service password reset, along with hardware solutions, such as fingerprint scanners and FIDO-key security keys. BIO-key solutions provide customers with unparalleled flexibility in securing all their access management needs and use cases. "We are very excited to partner with BIO-key. As renowned Cybersecurity experts and a leading Value-Added Reseller, this collaboration expands our capabilities and market reach and reinforces our commitment to delivering innovative solutions to our customers," said Peter Ejiofor, CEO of Ethnos. "With this partnership we look forward to expanding our international channel program," said Jose Frances, VP of Sales for Africa, Europe, and Brazil at BIO-key. "With Ethnos we have the ability to provide our unique IAM and Identity-Bound Biometrics solutions to their customers across Africa, leveraging their reputation as a trusted VAR and respected leader in the cybersecurity market."

08:37 EDT AMMO announces extension of share repurchase plan - AMMO announces that its Board of Directors approved an extension of the Company's share repurchase program for up to $30 million of its outstanding common stock until February 2024. Purchases made pursuant to the program will be made in the open market from time to time, at the Company's discretion, i through privately negotiated transactions or through other manners as permitted by federal securities laws. The timing, manner, price and amount of any repurchases will be determined by the Company and will be subject to economic and market conditions, stock price, applicable legal requirements and other factors. Previously, the Company disclosed in its Form 10-Q (Quarterly Report) filed on February 14, 2023 that approximately $29.7 million remained available for repurchases under the plan. The program is expected to continue following this public release and may be suspended or discontinued at any time prior to termination in February 2024.

08:35 EDT Adeia signs semiconductor patent license agreement with Western Digital - Adeia (ADEA) announced that Western Digital (WDC) entered into a long-term agreement to license Adeia's semiconductor patent portfolio, including those relating to hybrid bonding.

08:34 EDT Allison Transmission selected to equip AM General's A1 version of JLTV - Allison Transmission will provide the Allison 2500 Specialty Series, SP, transmission for AM General's A2 version of the Joint Light Tactical Vehicle, JLTV. The JLTV is used by the U.S. Army, Navy, Marine Corps and Air Force in addition to allied forces around the world. "Allison is extremely proud that the 2500 SP will remain the propulsion solution of choice for the JLTV," said Dana Pittard, Vice President, Defense Programs, Allison Transmission. "We are providing innovative propulsion solutions that meet the needs of our customer and deliver fuel efficiency technologies that offer on-the-move fuel economy improvements and anti-idle capability that optimize combat effectiveness of tactical wheeled vehicles."

08:33 EDT NanoVibronix receives final results of lifecycle testing of PainShield - NanoVibronix announced that independent life expectancy testing performed by Carmel Labs in Israel confirm that its PainShield met all tested functionalities. Brian Murphy, Chief Executive Officer of NanoVibronix, "Independent third-party testing results confirm that PainShield, our non-opioid, ultrasound therapy device for pain, met the defined testing parameters for lifecycle expectancy. We plan to submit the results of the testing to the Centers for Medicare and Medicaid Services to backfill our pending application for Medicare coverage." Murphy continued, "As you may recall, we were notified in September of 2022 by CMS that PainShield lacked sufficient life expectancy testing data, and therefore denied Medicare coverage. We subsequently commissioned the testing services of an independent, third party and received positive interim test results in January of this year. Today, we are confirming the testing is complete and the results were overwhelmingly positive. We believe these results clear the way for us to move forward with securing approval from CMS and ultimately making our device more widely available to those who could benefit from its use."

08:31 EDT Cryoport announces agreement with Inception Fertility - Cryoport announced a multi-year agreement with Inception Fertility, North America's largest provider of comprehensive fertility services. Inception Fertility operates The Prelude Network, the largest and fastest-growing technology-led network of fertility centers in North America, and MyEggBank, one of the largest and most diverse networks of donor egg banks and practices in North America. Through this three-year partnership, Prelude and MyEggBank will continue to utilize Cryoport's end-to-end supply chain solutions for egg and embryo shipments across their clinical networks to ensure significant risk mitigation for families using these services. Additionally, Prelude's patient medical record system will be integrated with Cryoport's Cryoportal 2.0, which will merge each shipment's tracking, condition monitoring and equipment qualification data into a single data stream, providing better service to Inception and Prelude's patients.

08:31 EDT SOBR Safe signs SaaS agreement with The Fox Group - SOBR Safe announced that it has signed a software as a service agreement with the Fox Group, based in British Columbia, Canada and with operations in the United States. The Fox Group is a leader in North American commercial driver education, counting Provincial Driver Training Institute, North Shore Driving School and Fox Professional Driver Training Centers among its portfolio holdings. The Fox Group will initially install the SOBRcheck alcohol detection technology in select Canadian locations, and then has targeted its entire training organization of over 3,500 employees and all student drivers for SOBRcheck expansion.

08:26 EDT Sprouts Farmers Market to eliminate single use plastic bags by end of 2023 - Sprouts Farmers Market announced it will eliminate single use plastic bags at checkout by the end of 2023. With this decision, Sprouts will remove over 200 million single use plastic bags from circulation each year. Sprouts has already eliminated single use plastic bags at 132 of its California stores and will roll out this initiative in phases next month, beginning with Nevada, Utah, Maryland, Pennsylvania and Virginia stores. Sprouts will offer customers stronger, reusable plastic bags made from 40% post-consumer recycled material that are designed to be reused at least 125 times and will continue to offer customers numerous other reusable bag options for purchase. Sprouts will encourage customers to bring their own reusable bags by charging ten cents per reusable plastic bag. The company has also stopped offering paper bags at checkout as paper bags are generally not reusable, often are not recycled and have a high environmental cost in terms of water, energy and raw materials used in their manufacture. Customers can continue to bring single use plastic bags to Sprouts stores for recycling after use; in 2022, customers recycled nearly one million pounds of soft plastics at Sprouts stores. Learn more about this initiative and Sprouts' sustainability efforts at sprouts.com/sustainability.

08:23 EDT Accenture, QuSecure team in first successful multi-orbit communications link - QuSecure announced that the company, in collaboration with Accenture, has accomplished the first successful multi-orbit data communications test secured with post-quantum cryptography, which refers to cryptographic methods that are secure against an attack by a quantum computer. This demonstrates that crypto-agility, successfully rotating to a less vulnerable algorithm, is real and possible. This outcome was accomplished through an Accenture-facilitated LEO data transmission. The entire transmission was secured using both classical cybersecurity and quantum-resilient cybersecurity utilizing QuSecure's QuProtect platform, all with no installation of software on the satellites. "Outer space is getting more crowded and contested every day, and providing reliable space-based security is critical in today's global economy," said Tom Patterson, Quantum and Space Security lead at Accenture. "Bringing advanced security capabilities like QuSecure's quantum-resistant crypto agility systems to orbit drives Accenture forward to better secure businesses on earth and throughout the space ecosystem."

08:21 EDT Sysco appoints Kenny Cheung to CFO - Sysco has appointed Kenny Cheung to the position of CFO, effective April 17, 2023. Neil Russell, who has served as Interim CFO since January 6, 2023, has been appointed to the newly created position of Chief Administrative Officer. Cheung joins Sysco with nearly 20 years of financial and operational executive experience. He most recently served as Executive Vice President, Chief Financial Officer at The Hertz Corporation (HTZ).

08:19 EDT HP Inc. announces line-up of gaming hardware, software - HP announced its latest line-up of gaming hardware and software designed to bring gamers everything they need to enjoy the games they love. The new OMEN Transcend 16 Laptop, OMEN 16 Laptop, Victus 16 Laptop, and a vast range of stunning OMEN monitors offer casual, hobbyist, lifestyle, and hardcore gamers the power and flexibility to play and work hard. To bring everything together, new enhancements in OMEN Gaming Hub offer a variety of performance and personalization features.

08:17 EDT H2O Innovation proposes cartridge filter cleaning solution - H2O Innovation announced that it has performed a cleaning-in-place for cartridge filters at a water treatment facility using its Genesys-PWT membrane cleaners. This new cleaning method could prevent water treatment facilities from disposing of millions of cartridge filters each year, thereby helping them reduce their plastic waste and achieve their sustainability objectives. Over time, the sediment collected on cartridge filters creates physical and chemical fouling, which causes their performance to drop. As a result, reverse osmosis (RO) plant operators need to conduct periodical cartridge filter replacement to maintain optimal membrane performance and are constrained to sending the old filters to landfill. In some plants, cartridge filter replacement occurs several times a year or even monthly, resulting in not only cartridge costs but also in substantial losses due to the downtime required for filter replacement. Some plants may have up to 20,000 cartridge filter units, making replacement time very significant.

08:16 EDT Covant and Boehringer Ingelheim team to develop novel ADAR1 inhibitor - Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant's ADAR1 program. The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients. Covant significantly accelerates drug discovery for challenging targets like ADAR1 by using its industry-leading platform, which combines high-throughput chemoproteomics-based screening in the native setting with structural proteomics. Covant is systematically applying its platform to discover novel, high-value first-in-class and best-in-class therapeutics.The Covant-Boehringer Ingelheim collaboration seeks to create an ADAR1 inhibitor that could be used in combination with other immunotherapies to increase their efficacy. To date, existing immunotherapies have revolutionized cancer treatment but only work in a minority of patients.Inhibiting ADAR1 has the potential to address this challenge by transforming "cold" tumors into "hot" tumors, which have more immune cells present in the tumor micro-environment. "ADAR1 is an exciting immuno-oncology target with significant therapeutic potential," said Lamine Mbow, Global Head of Cancer Immunology & Immune Modulation, Boehringer Ingelheim. "We are committed to transforming the lives of cancer patients by delivering meaningful advances with the ultimate goal of curing a range of cancers. By partnering with Covant's exceptional scientific team and powerful platform, we aim to bring next-generation immunotherapies to cancer patients." Under the terms of the agreement, Covant will be responsible for the discovery of ADAR1 small molecule inhibitors. In turn, Covant will receive an upfront payment of $10M and will be eligible for up to $471M in additional milestone payments along with tiered royalties on global sales. Covant Therapeutics is a Boston-based covalent drug discovery company that was incubated by Roivant Sciences (ROIV). Covant creates novel therapeutics by using covalency to imprint and regulate proteins. To discover these therapeutics, the company applies cutting-edge capabilities and expertise in chemistry, quantitative proteomics, translational sciences, and deep learning.

08:16 EDT Brainsway announces publication of post-marketing data analysis for Deep TMS - BrainsWay announced the publication of an expansive post-marketing data analysis demonstrating high response and remission rates for depression and anxious depression patients undergoing Deep Transcranial Magnetic Stimulation treatment. The data, published in Psychiatry Research, showed the substantial benefits of Deep TMS treatment for depression, with patients who had received 30 or more treatments achieving an 82% response rate and a 65% remission rate. In the study, BrainsWay collected an aggregate data set from 1,753 patients across 21 clinics, of which 1,351 patients met the inclusion criteria for the analysis. All patients were treated with the Deep TMS H1 Coil utilizing either a standard protocol or a shorter intermittent theta burst protocol. Outcomes were measured with clinician-based scales and/or patient self-administered questionnaires designed specifically for depression. This analysis showed that the average patient achieved sustained response at 16 sessions, or 21 days after beginning treatment. The evidence also showed that efficacy rates were similar between the standard and iTBS protocols. Data from questionnaires which are not specific to depression, and thus less relevant for assessing depression changes, were intentionally excluded.

08:15 EDT IperionX, Canyon to improve sustainability in bicycle industry supply chain - IperionX partners with Canyon Bicycles to develop a more sustainable titanium supply chain for the bicycle industry through the production of bicycle components using IperionX's 100% recycled and low-carbon titanium. IperionX is working closely with Canyon's product development and ESG teams to produce bicycle components using IperionX's low-carbon, recycled titanium metal powders via additive manufacturing methods. The parties have agreed upon an initial project to prototype Canyon bicycle parts, including for bicycle frames, using IperionX's 100% recycled titanium produced by IperionX via additive manufacturing methods. The term of this initial agreement is until June 30, 2025. Upon successful completion of the initial prototyping, Canyon and IperionX intend to negotiate an agreement for larger scale production.

08:12 EDT Waters Eaton appoints Fearon to board of directors - Waters Corporation (WAT) announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation (ETN), a multinational power management company. As previously disclosed, Edward Conard, a director since 1994, will retire from the Waters Board at the Company's 2023 Annual Meeting. Following the Meeting, the Board will be comprised of nine members, three of whom have been appointed in the last year.

08:09 EDT PagerDuty introduces first Process Automation solution PagerDuty Operations - PagerDuty announced the newest PagerDuty Process Automation release within its essential infrastructure for critical work, the PagerDuty Operations Cloud solution. These updates enable organizations to orchestrate automation across secure cloud and data center environments. "Most organizations have automation operating across cloud, non-cloud, and distributed infrastructures which have some of the highest security and compliance requirements," said Sean Scott, Chief Product Development Officer at PagerDuty. "Engineers can now rely on the PagerDuty Process Automation solution to meet these requirements while speeding up their ability to deploy changes and innovation."

08:09 EDT Immuneering appoints Harold Brakewood as CBO - Immuneering Corporation (IMRX) announced that it has appointed Harol Brakewood as its Chief Business Officer. Mr. Brakewood, who has more than 25 years of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development, new product planning, and commercial strategy. He joins Immuneering from Regeneron (REGN) Pharmaceuticals where he most recently served as Vice President, Business Unit Head for oncology, Covid-19, and new product planning.

08:08 EDT Lantern Pharma doses first patient in Phase 2 Harmonic clinical of LP-300 - Lantern Pharma announced the dosing of the first patient in the Phase 2 Harmonic clinical trial evaluating Lantern's investigational new drug LP-300 in combination with chemotherapy for never smokers with advanced non-small cell lung cancer, NSCLC. "Never-smokers with non-small cell lung cancer face limited choices in therapy options after treatment with targeted therapies, and we believe there is a great opportunity to introduce a therapeutic regimen designed specifically for this subgroup of cancer patients," stated Reggie Ewesuedo, M.D., M.Sc., MBA, Lantern Pharma's VP of Clinical Development. "These patients show tremendous bravery and resolve in helping to establish signals of efficacy including potential increased survival in this Phase 2 trial that combines LP-300 with standard-of-care treatment. Our team continues to watch and monitor additional patients that are being screened and who, after guidance from their clinicians, may potentially enroll in the Harmonic(TM) trial," continued Dr. Ewesuedo.

08:07 EDT Uber Eats launches U.S. certified virtual restaurant program - Uber Eats announced a new Certified Virtual Restaurant Program. This initiative, launched in partnership with leading brand builders Virtual Dining Concepts, Nextbite and Acelerate, aims to make virtual restaurant operations more streamlined and effective for merchants, and to create a more consistent, reliable virtual restaurants experience for consumers who use Uber Eats. The program is part of an ongoing effort at Uber to refocus its virtual restaurant operations-which has accelerated massively in the wake of the pandemic to over 40,000 virtual storefronts-with an emphasis on quality for the benefit of consumers and merchants across the country. The Certified Virtual Restaurant Program allows merchants to tap into a pipeline of virtual restaurant concepts curated by Uber and vetted to meet high-bar standards in menu quality, operations, and branding.

08:05 EDT Acrivon Therapeutics expects cash to fund operations into 4Q24 - As of December 31, 2022, the company had cash, cash equivalents and marketable securities of $169.6 million, which is expected to fund operations at least into the fourth quarter of 2024.

08:04 EDT BioAffinity Technologies announces publication of paper on CyPath Lung test - bioAffinity Technologies announced the publication of a paper titled "Porphyrin-modified beads for use as compensation controls in flow cytometry" in the peer-reviewed Journal of Visualized Experiments, JoVE. The paper describes the protocol for preparing porphyrin-labeled compensation beads to optimize the results of bioAffinity's CyPath Lung test to detect early-stage lung cancer. bioAffinity Technologies has an international patent pending for the proprietary compensation beads and their use in flow cytometry. "The publication of our peer-reviewed paper in JoVE is a recognition of our commitment to advancing innovative science in line with the Company's mission of improving the survivability of lung cancer, the world's deadliest cancer, through expanded screening and early diagnosis," said Maria Zannes, President and CEO of bioAffinity Technologies.

07:57 EDT Lilium, Customcells ramp up silicon anode battery cell production - Lilium and Customcells are ramping up battery cell production of Lilium's high silicon content cells with weekly deliveries from Customcells production line in Tubingen, Germany. The production line will deliver thousands of cells annually and is on track to meet aviation standards for traceability and process control using a combination of standard cell production processes and a pre-lithiation process for high silicon content cells. Lilium partners with Ionblox for its exclusive silicon anode cell technology that allows for greater energy and power density combined with high cycle life. Following their partnership announcement in 2021, Customcells and Lilium are now successfully leveraging a pre-lithiation process that the companies are further industrialising towards volume production. The pre-lithiation process, a key advantage for enabling greater energy and power density, inserts additional lithium to compensate for the loss of lithium during the first cycle. Furthermore, Customcells' production traceability will enable Lilium to meet aviation standards and support production certification needs by delivering process-level and cell-level data to Lilium. Lilium remains on track to start production of its type-conforming aircraft later this year and plans for first manned flight of the type-conforming aircraft in the second half of 2024.

07:53 EDT ZW Data Action Technologies teams with Chaineffect in the field of AI - ZW Data Action Technologies, an integrated online advertising, precision marketing, data analytics, and other value-added services company, announced that it has entered into a cooperation agreement with Chaineffect, Guangzhou, Blockchain Technology a People's Republic of China company pursuant to which the parties will collaborate in areas such as Artificial Intelligent Generated Content, AIGC, AI-derived service products under the Aichat brand for market expansion, software and hardware product research and development, and the promotion of application scenarios. Under the agreement, ZW Data and Chaineffect will cooperate in two aspects: first, based on the existing Aichat products, the two companies will jointly establish a sales team to leverage ZW Data's resources of thousands of franchisees and its domestic and overseas market promotion capabilities to promote the Aichat products. ZW Data's small and medium-sized enterprise clients have tens of thousands of brand stores, and their customer service and store service businesses will all be service targets for Aichat products. Second, ZW Data will use its blockchain technology to collaborate with Chaineffect on research and development, expand product categories, and explore multiple commercial scenarios such as learning and education, health management, and e-commerce marketing. Additionally, the parties plan to launch commercial solutions to provide one-stop digital upgrade services for end customers.

07:51 EDT Semantix launches Semantix Data Marketplace - Semantix announced the launch of Semantix Data Marketplace, a new product that enables customers to leverage organized and curated third-party data. The Semantix Data Marketplace offers a collection of public data sources that are expertly organized and curated within the Semantix Data Platform, strictly following data protection laws and regulations. With just a few clicks on the SDP, customers from different industries such as health, retail, and finance, can connect to these datasets, enrich their internal datasets, and gain valuable insights.

07:49 EDT SL Green signs full floor lease with Palo Alto Networks at One Madison Avenue - SL Green Realty (SLG), Manhattan's largest office landlord, announced that Palo Alto Networks (PANW), a global cybersecurity company, has signed a long-term lease covering an entire tower floor at One Madison Avenue, bringing SL Green's 2023 signed office leasing volume to 491,913 square feet, while the Company's office leasing pipeline has increased to over 1M square feet, up from a 700,000 square feet pipeline just three weeks ago. The 1.4M square foot transformational development at One Madison Avenue, is scheduled for completion in October 2023, approximately 5 weeks ahead of original timeline - and is now 59% leased.

07:46 EDT Adamas One expects $12M in revenue from Greenville, South Carolina factory - Adamas One provides a business update for investors regarding the ramp-up of its expanded factory facilities in South Carolina. The Company now has 12 full-capacity reactors that are growing diamonds at a rate of approximately 3,000 rough carats of diamonds a month. Based on the rate of production, Adamas One management believes that it will begin to receive additional revenue by mid-summer 2023. With reactors at their full production capacity and full marketing underway, the Company anticipates more than $12M in annual sales revenue from the current factory in Greenville, South Carolina.

07:45 EDT ARway files provisional patent for digital twin floor plan generation technology - Arway Corp. filed a provisional patent for their digital twin technology to create and manage virtual replicas of physical spaces. ARway's technology is unique in that it eliminates the complexity and reliance on expensive hardware and scanners by ingesting 2D floor plans and architectural drawings and converting these artifacts into 3D environments. It achieves this by combining position data from the real world and image pixels of the floor plan and transforming them using a 3D engine into an augmented reality layer to the digital twin, allowing for real-time information to be overlaid onto the physical environment. The use of digital twins technology has been gaining popularity in recent years, however, traditional methods rely heavily on IoT sensors to generate a digital overlay of the physical environment. ARway's innovative approach to creating digital twins simplifies the process by allowing properties to create 3D replicas of their space with just a 2D floor plan, using our 3D web Studio. This lightweight solution is accessible to any venue with a floor plan, democratizing access to digital twin technology. By providing an easy-to-use solution, ARway can reach a wider market, increasing the likelihood of successful adoption. Moreover, patenting ARway's technology protects the Company from competition, ensuring its position at the forefront of digital twin technology innovation in the indoor wayfinding and AR experience space. ARway's technology is a game-changer, providing an affordable and accessible solution for businesses to create and manage digital twins of their physical spaces.

07:40 EDT Hess Midstream announces signing of accretive $100M sponsor unit repurchase - Hess Midstream announced the execution of a definitive agreement providing for the approximately $100M repurchase of Class B units by its subsidiary, Hess Midstream Operations, from affiliates of Hess Corporation and Global Infrastructure Partners, Hess Midstream's sponsors. The terms of the proposed unit repurchase transaction were unanimously approved by the Board of Directors of Hess Midstream's general partner. Pursuant to the terms of the repurchase agreement, the repurchased units will be cancelled upon the closing of the unit repurchase transaction, which is expected to result in increased distributable cash flow per Class A share providing capacity for incremental distribution growth above Hess Midstream's 5% annual distribution target, consistent with Hess Midstream's return of capital framework. Hess Midstream Operations LP, Hess Midstream's consolidated subsidiary, agreed to repurchase 3,619,254 Class B units of Hess Midstream Operations LP, equal to approximately 1.5% of the consolidated company, held by the Sponsors for an aggregate purchase price of approximately $100 million. The purchase price per Class B unit is $27.63, the closing price of the Class A shares on March 27, 2023. As a result of the unit repurchase transaction, public ownership of Hess Midstream on a consolidated basis will increase to approximately 18.3%. The terms of the proposed unit repurchase transaction were unanimously approved by the Board, based on the approval and recommendation of its conflicts committee composed solely of independent directors. The unit repurchase is anticipated to close in March 2023. Hess Midstream expects to fund the unit repurchase through borrowings under its existing revolving credit facility.

07:40 EDT Ameresco, Redflow partner to provide advanced non-lithium energy storage - Ameresco and Redflow Limited announced a strategic relationship through which Redflow will supply Ameresco, on a non-exclusive basis, with its advanced non-lithium battery energy storage technology. Ameresco plans to utilize this technology for its project and asset installations for a wide array of customers. Ameresco's portfolio includes energy efficiency, infrastructure upgrades, asset sustainability, and renewable energy solutions delivered to clients throughout North America and Europe. Redflow's non-lithium energy storage system will be used by Ameresco for medium- to long-duration deployments and daily cycling applications in its integrated cleantech solution portfolio. Ameresco plans to deploy Redflow's zinc-bromine flow batteries as part of a flexible and modular integrated solar and storage solution, which is being designed to meet the increasing need in the market for medium- and long-duration systems.

07:38 EDT Vera Therapeutics sees balance sheet funding operations to early 2026 - Vera reported $114.7 million in cash, cash equivalents, and marketable securities as of December 31, 2022. Subsequent to December 31, 2022, the company raised approximately $107.6 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses, from a public offering of its Class A common stock that was completed in February 2023.

07:37 EDT Vera Therapeutics announces upcoming milestones - 36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN on track for the second quarter of 2023; Expect to initiate Phase 3 clinical trial of atacicept in IgAN in second quarter of 2023; Plan to present data from the ongoing ORIGIN trial in 2023.

07:35 EDT Tokens.com's Metaverse Group enters partnership with Lancia Italia - Tokens.com announces that its subsidiary, Metaverse Group, has partnered with Lancia Italia, to be its official automotive brand partner for Metaverse Fashion Week 2023. Metaverse Fashion Week 2023 is set to take place from March 28th to 31st with the heart of the event in Metaverse Group's Luxury District, where Lancia Italia will have its virtual showroom. Lancia is the first automaker to partner with Metaverse Group. This partnership with Lancia helps promote the European automaker to a larger audience given Metaverse Fashion Week's global presence. In turn, Metaverse Group has the opportunity to display its metaverse builds that were created using in-house services on a larger scale. "As leaders in web3 community development, we are here to help guide and provide brands with new, exciting, and innovative ways to meet new objectives as web3 is gaining popularity daily," said Andrew Kiguel, CEO of Tokens.com and Executive Chairman of Metaverse Group. " We are thrilled to be partnering with Lancia on their web3 journey."

07:27 EDT Parsons awarded $94M contract by United States Cyber Command - Parsons was selected to provide command, control, communications, computers, and capabilities development support services to United States Cyber Command. The $94M cost-plus-fixed-fee contract complements work awarded to Parsons to support the agency's C4CD mission set and consists of one 12-month base period of performance with four 12-month option periods.

07:25 EDT Laser Photonics receives order from GE Gas Power for CleanTech system - Laser Photonics announced it received an order from GE Gas Power for an LPC-300CTH CleanTech laser blasting system for turbine maintenance and repair operations. GE Gas Power added Laser Photonics as an approved supplier for laser cleaning technology. The dual-axis CleanTech LPC-300CTH will be utilized by GE Gas Power's energy division in its turbine maintenance program to extend product life while improving maintenance speed. The laser cleaning technology will also be available to other GE departments for application testing.

07:24 EDT Silence Therapeutics appoints Romano as Incoming Chief Medical Officer - Silence Therapeutics (SLN) announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion's retirement by year-end. Dr. Romano has served as non-executive director of the Silence Board since July 2019 following the Company's siRNA collaboration with Mallinckrodt plc for complement-mediated diseases. Most recently, Romano served as executive vice president and chief scientific officer at Mallinckrodt (MNK) and was responsible for research and development, medical affairs, health economics and outcomes research, safety, pharmacovigilance and regulatory affairs functions.

07:20 EDT Vicinity Motor closes C$4M convertible debenture financing - Vicinity Motor announced the closing of a non-brokered private placement of unsecured convertible debentures for gross proceeds of C$4M. Net proceeds from the Private Placement will be deployed to accelerate vehicle production and deliveries in the Company's existing $150M order backlog. The Convertible Debentures are issued in denominations of C$1,000, bear interest at 15% per annum, and mature 18 months from the closing date. Interest payments on the Convertible Debentures have been deferred to the twelve-month anniversary and/or maturity. Each Convertible Debenture is convertible at the holder's option into units of the Company at any time prior to maturity at a conversion price of C$1.45. Upon conversion, each Unit will consist of one common share of the Company and 0.2 common share purchase warrants. Each Warrant is exercisable into one Common Share of the Company at an exercise price of C$1.45 for a period of thirty-six months following the closing of the Private Placement. All securities issued under the Private Placement have a hold period of four months and a day from closing. The Private Placement is subject to final TSX Venture Exchange approval. In connection with the Private Placement, Vicinity paid cash commissions to eligible finders, in accordance with TSX Venture Exchange policy, of C$73,500.

07:18 EDT Voyager presents new data data for AD and GBA1 gene therapy for PD treatments - Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer's Disease and GBA1 Gene Therapy Program for Parkinson's Disease at the AD/PD ) ConferenceVoyager Therapeutics presented new data from its anti-tau antibody program for Alzheimer's disease AD and from its GBA1 gene therapy program for Parkinson's disease (PD) and other GBA1-mediated diseases at the AD/PD Conference in Gothenburg, Sweden. "Voyager continues to advance multiple programs towards the clinic. For our anti-tau antibody program for Alzheimer's disease, these new preclinical data support our recent selection of VY-TAU01 as the lead development candidate, with an IND filing expected in the first half of 2024," said Todd Carter, Ph.D., Chief Scientific Officer at Voyager. "For our GBA1 gene therapy program with Neurocrine for Parkinson's disease, these new data from a GBA1 loss of function mouse model show effects of three GBA1 gene therapy candidates on multiple endpoints." These new data from additional mouse efficacy studies showed that all three candidates demonstrated significant improvement in several efficacy biomarkers.

07:17 EDT Mindset Pharma to expand efforts into novel non-hallucinogenic therapeutics - Mindset Pharma issued a letter to shareholders from James Lanthier, CEO, which read in part, "Mindset entered 2023 with a robust pipeline of novel psychedelic-inspired drug candidates advancing towards first-in-human clinical trials. More importantly, these candidates are supported by an industry leading intellectual property portfolio. Mindset is planning to initiate human trials of its novel and patentable prodrug of psilocin, MSP-1014, shortly. MSP-1014 is our proprietary lead Family 1 drug candidate that we view as a best-in-class "second generation" psilocybin analog with improved safety, efficacy and tolerability signals. MSP-1014 is rapidly metabolized to psilocin, the main active metabolite of psilocybin, and is likely to exert similar efficacy and better tolerability to psilocybin in improving symptoms of depression in difficult to treat patient populations. In November, Mindset announced data from preclinical studies examining MSP-1014 side-by-side to psilocybin across a battery of preclinical studies evaluating safety, behavioral and pharmacokinetics properties. The data shows that MSP-1014 attenuates the reduction of locomotor activity and body temperature seen with psilocybin, suggesting that the tolerability of MSP-1014 may be superior to psilocybin. Moreover, these improvements were evident in conjunction with increased effect in assays evaluating cardinal signs of 5-HT2A target engagement, suggesting that it may be possible to achieve a similar or greater psychedelic effect with MSP-1014 as psilocybin, but with improved tolerability. The Family 2 program compounds are being developed as optimized next-generation psychedelic drug candidates for the treatment of mental health disorders in collaboration with the McQuade Center for Strategic Research and Development, a member of the Otsuka family of pharmaceutical companies. In October of 2022, after extensive preclinical screening studies, Mindset announced the selection of MSP-2020 as its lead drug candidate, and MSP-2003, as a back-up drug candidate, to advance into IND-enabling studies with a leading global Contract Research Organization. In side-by-side comparisons to psilocybin and psilocin, both lead drug candidates elicit in vitro and preclinical behavioral responses consistent with greater potency than LSD combined with a shorter psychedelic effect than psilocybin...Thanks to our early focus on novel drug development, Mindset's scientific team has developed a rich understanding of the structure-activity relationships of psychedelic drug structures. We are now applying this knowledge towards discovering novel psychedelic-inspired non-hallucinogenic drug candidates. This work has been underway for some time and, to date, Mindset has discovered multiple candidates with a promising preclinical profile. Therapeutics that deliver pro-cognitive benefits at doses without hallucinogenic effects have the potential to treat substantially wider patient populations extending beyond depressive disorders. By reducing or removing the psychedelic effect, in-clinic supervision may not be necessary, reducing cost and improving convenience. Additionally, non-hallucinogenic drug candidates are potentially more appropriate for treating fragile population groups such as children or geriatric patients. Mindset recently filed a U.S. provisional patent application expanding its breadth of non-hallucinogenic, psychedelic-inspired, compounds beyond its previously announced "Family 3." These new non-hallucinogenic compounds are derived from its non-tryptamine scaffolds, known as families 6-8. In preclinical screening, these candidates exhibit 5-HT2A activation, but without the cardinal in vivo signs of a hallucinogenic effect. We are eager to continue our discovery work surrounding these novel non-hallucinogenic psychedelic inspired compounds given the breadth of potential neurological and psychiatric disorders that they may address. We expect to make further announcements in the near future around additional IP filings in this field of research as our discovery work progresses."

07:15 EDT TravelCenters confirms ARKO proposal not superior to BP transaction - TravelCenters of America (TA) confirmed that the Board of Directors previously reviewed and determined that the conditional, unsolicited and unfinanced proposal from ARKO (ARKO) to acquire TA is neither superior to the transaction TA previously agreed to with BP Products North America (BP) nor is it likely to lead to a superior proposal. In a news release and letter to TA, both distributed on March 27, 2023, ARKO restated the terms of its March 14, 2023 proposal and asked TA's Board to reconsider its proposal. On March 14, 2023, ARKO submitted an unsolicited, non-binding indication of interest to acquire TA. Following a comprehensive review with its financial and legal advisors, the TA Board unanimously concluded that ARKO's proposal did not constitute a superior proposal and could not reasonably be expected to lead to a superior proposal. Among the reasons the Board determined that ARKO's proposal was neither a superior proposal nor likely to lead to a superior proposal was the high level of execution risk resulting from ARKO's failure to obtain committed financing and that ARKO's sub-investment grade credit rating was not attractive to Service Properties Trust (SVC), the landlord of most of TA's properties.

07:13 EDT Tiziana intends to start Phase 2 trial of intranasal foralumab in Q3 - Tiziana Life Sciences received feedback based on the U.S. Food and Drug Administration Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active SPMS. Tiziana plans to accept the FDA's recommendations and intends to start a Phase 2 study in the third quarter of 2023 as previously announced. Foralumab is the only fully human anti-CD3 monoclonal antibody.

07:12 EDT Oscar Health announces appointment of Bertolini as CEO - Oscar Health announced the appointment of Mark Bertolini to the role of Chief Executive Officer, CEO, effective April 3, 2023. Co-Founder Mario Schlosser, will transition to President of Technology, reporting to Mark. In his new role, Mario will lead product and engineering, with a focus on building Oscar's tech platform for the future and continuing to set the strategy for the +Oscar roadmap. Bertolini is a national healthcare thought leader, and the former Chairman and CEO of Aetna. Schlosser will continue as a member of the Board of Directors, and the Board will be expanded to add Bertolini.

07:12 EDT Aslan Pharmaceuticals regains compliance with Nasdaq listing rules - ASLAN Pharmaceuticals received written notice from The Nasdaq Stock Market stating that the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. The Company was previously notified by Nasdaq on March 28, 2022, that it was not in compliance with the minimum bid price requirement because the bid price of the Company's American Depositary Shares closed below $1.00 for 30 consecutive business days. In order to regain compliance with the minimum bid price requirement, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least ten consecutive business days, which was achieved on March 27, 2023. Accordingly, the Company has regained compliance with Nasdaq's minimum bid price requirement and the Company's ADSs will continue to be traded on The Nasdaq Capital Market, subject to the Company's continued compliance with all applicable continued listing standards.

07:10 EDT Bicycle Therapeutics announces strategic collaboration with Novartis - Bicycle Therapeutics (BCYC) announced that it has entered into a strategic collaboration agreement with Novartis (NVS) to develop, manufacture and commercialize Bicycle radio-conjugates, BRCs, for multiple agreed upon oncology targets. "This collaboration builds on the groundbreaking clinical work we have been doing in the toxin conjugate field and provides new and additional validation for this unique technology," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "We look forward to working closely with Novartis to pioneer the discovery and development of potential new cutting-edge radiopharmaceutical cancer treatments based on Bicycles. We believe the properties of Bicycles make them well suited for the development of precision guided radiopharmaceuticals and represents the next leg in the application of our proprietary discovery platform in oncology." Under the terms of the agreement, Bicycle will utilize its proprietary phage platform to discover Bicycles to be developed into BRCs. Novartis will be responsible for further development, manufacture and commercialization of the BRCs. Novartis will fund all pre-clinical and clinical development and commercialization activities. Bicycle will receive a $50M upfront payment and is eligible for development and commercial-based milestone payments totaling up to $1.7B. Bicycle will also be eligible to receive tiered royalties on Bicycle-based medicines commercialized by Novartis.

07:09 EDT Intra-Cellular: Study 403 of lumateperone met primary endpoint for MDD - Intra-Cellular Therapies announced positive topline results from Study 403 evaluating lumateperone 42mg as monotherapy in the treatment of major depressive episodes in patients with major depressive disorder with mixed features and in patients with bipolar depression with mixed features. Lumateperone 42mg given once daily met the primary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the MADRS total score compared to placebo at Week 6. "Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population "

07:08 EDT Ceragon Networks announces $29M in follow-on orders from Tier 1 Operators - Ceragon Networks announced that since the beginning of 2023 it has received follow-on orders of $29M from Tier 1 Operators in India for deployment in 2023. The orders include both hardware and services focused on upgrading existing network capabilities to 5G, expanding capacity, improving rural connectivity, and providing customers with reliable uninterrupted high-speed experiences. The delivery and deployment of Ceragon's products and services are expected primarily in Q2 and Q3, 2023.

07:06 EDT Crescent Point Energy to acquire Spartan's Montney assets for C$1.7B - Crescent Point Energy announced that it has entered into an agreement with Spartan Delta to acquire Spartan's oil and liquids-rich Montney assets in Alberta for C$1.7B in cash. Highlights include: Acquisition adds 600 Montney locations in Alberta, or over 20 years of premium drilling inventory; immediately accretive to excess cash flow per share by 20%, resulting in a higher return of capital for shareholders; maintaining commitment to return approximately 60% of excess cash flow to shareholders, including the base dividend; pro-forma leverage ratio of 1.3 times adjusted funds flow at closing and 1.0 times at year-end 2023; targeting additional non-core asset dispositions over time to further optimize portfolio. Key attributes of the acquired assets include the following: approximately 38,000 boe/d with attractive netbacks generating significant excess cash flow; total drilling inventory of 600 net Montney locations, providing over 20 years of inventory to sustain current production levels; approximately 235,000 net acres of contiguous land with Montney rights in Alberta within the Gold Creek and Karr area; consolidated land base that is primarily Crown with a high average working interest of 96%; situated in the volatile oil fairway with attractive reservoir characteristics, including pay thickness and permeability; key infrastructure and well licenses in place to support future development plans; adjacent to Crescent Point's Kaybob Duvernay assets, providing opportunity for operational efficiencies; C$1.7B of tax pools to further enhance long-term excess cash flow generation; and low Scope emissions intensity of less than 0.01 tCO2e/boe. Type wells for the acquired assets are expected to payout in approximately 10 months from the initial on-stream date. Upon closing, the Company's pro-forma decline rate is expected to remain below 30%. The Transaction is anticipated to close during Q2.

07:05 EDT Plus Therapeutics treats 1st patient in Cohort 8 of ReSPECT-GBM Phase 1/2a trial - Plus Therapeutics announced the first patient in Cohort eight of the ReSPECT-GBM Phase 1/2a dose escalation clinical trial evaluating the Company's lead investigational targeted radiotherapeutic, rhenium obisbemeda, in recurrent glioblastoma GBM has been successfully treated.The dose escalation phase of the trial has now treated 25 patients with no dose-limiting toxicities observed through 7 completed dosing cohorts. Cohort 8 is now enrolling using 41.5 millicuries ( administered dose rhenium obisbemeda with an infused volume of 16.34 milliliters which allows the treatment of large and morphologically complex tumors...In parallel, the Company has treated five patients to date with rhenium obisbemeda in the Phase 2 trial in recurrent GBM administering a dose of 22.3 mCi and 8.8 mL in small- to medium-sized tumors."Taken together, the safety and efficacy signals observed thus far in 30 treated recurrent GBM patients are very promising," said Norman La France, M.D., President and Chief Medical Officer of Plus Therapeutics. "We remain on track in 2023 to continue to dose escalate to the yet unreached maximal tolerated dose, expand the number of clinical trial sites and present data from the Phase 1/2a and 2 trials in the second half of 2023."Thus far, no treatment emergent dose-limiting toxicities have been observed in either trial. The absorbed radiation doses from the 30 patients treated to date have resulted in an absorbed dose of up to 740 gray to the tumor.The U.S. Food and Drug Administration granted both Orphan Drug designation and Fast Track designation to rhenium obisbemeda for the treatment of GBM. More information about the ReSPECT-GBM trial may be found at ReSPECT-Trials.com and ClinicalTrials.gov .

07:04 EDT Revive enrolls patient in psilocybin study for methamphetamine use disorder - Revive Therapeutics provides an update on the Company's Phase I/II clinical study evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy. Under an investigator-initiated IND, led by Dr. Christopher Nicholas, PhD, the Study has enrolled its first patient and initial results are expected in Q3-2023. The clinical data generated from the Study may provide proprietary and valuable information on the safety, efficacy and dosing of oral psilocybin to support potential research and commercial initiatives in countries, such as Australia, where psilocybin can be available to specially-licensed psychiatrists to prescribe for certain conditions and future clinical studies for the Company's proposed psilocybin oral thin film strip and transdermal microneedle patch products. In addition, the Company will have exclusive access to key intellectual property from this Study to support development, regulatory and commercial initiatives. Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. At present, there are no approved medications to treat methamphetamine use disorder. Psilocybin-assisted psychotherapy is emerging as a promising treatment for a range of difficult-to-treat conditions, including substance use disorders, however, no studies have yet been published looking at psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder.

07:02 EDT Lantronix announces X300 Cellular Compact IoT Gateway Solution - Lantronix announced its new X300 Compact Gateway IoT Solution. The new X300 Cellular Compact IoT Gateway Solution combines Lantronix's IoT gateway hardware with a premium services subscription, including centralized device management, integrated cellular data, enhanced device security and expert technical support in an all-in-one package.

06:54 EDT Synlogic receives positive EMA opinion on orphan designation for SYNB1934 - Synlogic announced that the European Medicines Agency issued a positive opinion on the company's application for orphan designation for SYNB1934 for the treatment of phenylketonuria. "We are pleased that the EMA has issued a positive opinion for orphan designation for SYNB1934, in recognition of the urgent need for new treatment options for people living with this devastating disease," said Aoife Brennan, M.B. Ch.B., Synlogic President and CEO. "This designation also comes at a pivotal time as we prepare to begin our Phase 3 trial for PKU in the first half of this year."

06:50 EDT Entain selected by TAB New Zealand as preferred partner for 25-year pact - Entain plc announces that it has been selected by TAB New Zealand as its preferred partner for a 25-year strategic arrangement. "Entain was selected based on a wide range of criteria, including operational expertise, cultural alignment with TAB NZ and its commitment to uplifting TAB NZ's harm minimisation and responsible gambling efforts. The proposed strategic arrangement, and timing of completion, remains subject to approval from the New Zealand Minister for Racing. Further information, as appropriate, will be provided after the completion of the Ministerial approval process," the company stated. Reference Link

06:47 EDT Chemours announces long-term glycolic acid sustainability program - The Chemours Company announced a long-term sustainability program for its glycolic acid product portfolio to address growing consumer demand for sustainable products at the 2023 in-cosmetics Global tradeshow. The sustainability program's ultimate goal is to reduce the carbon footprint of all of Chemours' glycolic acid grades by 80% against a 2023 baseline.

06:37 EDT Hut 8 Mining files amended claim against Validus Power, Bay Power - Hut 8 Mining served and filed an amended statement of claim in the Ontario Superior Court of Justice against Validus Power Corp. and its subsidiary, Bay Power Corp., a third-party supplier of energy to the Company's mining facility in North Bay, Ontario.The Amended Claim relates to the Company's ongoing and previously disclosed dispute with Validus in respect of Validus' failure to meet its contractual obligations under the power purchase agreement it entered into with the Company. In addition to the claims set out in the original statement of claim, the Amended Claim, among other things, adds claims involving the associated lease between the Company and Validus at the Company's mining facility in North Bay, Ontario to include a claim for unlawful termination by Validus of the aforementioned lease. The Company does not intend to make additional comments on this subject unless otherwise determined to be appropriate.

06:30 EDT Gravity: Ragnarok Origin will be launched in Southeast Asia on April 6 - Gravity announced that Ragnarok Origin will be launched in Southeast Asia on April 6. Ragnarok Origin has exceeded 3M accounts in the pre-registration in Southeast Asia.

06:08 EDT Athira Pharma presents preclinical data about fosgonimeton at AD/PD 2023 - Athira Pharma presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD/PD 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, or AD/PD. Data presented in three poster presentations highlight the effects of fosgonimeton or fosgo-AM, acting through the HGF/MET pathway, demonstrating: significant protection from neurite degeneration and cell death in cultures of primary cortical or dopaminergic neurons challenged with several neurological insults central to Alzheimer's and Parkinson's disease pathologies; protection from protein pathologies, including significantly reduced levels of hyperphosphorylated tau in cortical neurons treated with toxic amyloid beta, and significantly lower levels of alpha-synuclein aggregation in dopaminergic neurons treated with toxic insults; and significant anti-inflammatory effects on immune cells in vitro and significant procognitive activity in a model of neuroinflammation-induced cognitive impairment in vivo.

06:05 EDT Greyhound Lines partners with Paysafe - Greyhound Lines has partnered with payments platform Paysafe to roll-out online cash services. Greyhound customers can now use Paysafe's eCash solution Paysafecash to make safe and secure cash payments when booking a trip online. To purchase an online ticket with cash, Greyhound customers select 'cash' as the payment method at the checkout. This generates a barcode that can be paid at one of more than 70,000 participating convenience stores, pharmacies or dollar stores that offer Paysafecash payment services. The customer presents the barcode at the cash register to complete the purchase.

05:56 EDT Fusion Fuel enters 10-year hydrogen purchase agreement with Hydrogen Ventures - Fusion Fuel announced that it has signed a ten year offtake contract with European developer Hydrogen Ventures Ltd for thirty tonnes of green hydrogen per annum. First orders are expected to be delivered in the fourth quarter of 2023. The hydrogen will be produced at the company's projects in Evora, Portugal, where Fusion Fuel is expanding its production capacity to roughly 50 tonnes per annum by year end. Hydrogen Ventures, which is developing a pipeline of green hydrogen projects and entering into supply contracts with local industrial and municipal customers, expects to use the hydrogen for mobility applications in Portugal. This contract represents Fusion Fuel's second hydrogen purchase agreement in Portugal to date, providing long-term stability and price security to the nascent hydrogen ecosystem: a critical step forward in the creation of a more robust and competitive market for green hydrogen.

05:53 EDT Diageo CEO Ivan Menezes to retire, Debra Crew to succeed - Diageo announces that Sir Ivan Menezes has decided to retire as CEO and depart from the Diageo Board on June 30, following ten successful years leading the company. Debra Crew, currently COO, will be appointed CEO and join the Diageo Board, effective July 1. Debra is the former President and CEO of Reynolds American, where she delivered strong performance growth before the company's acquisition, having previously served as President and COO, and President and Chief Commercial Officer. Prior to being appointed COO in October 2022, Debra was President, Diageo North America and Global Supply, leading Diageo's largest market to 14% organic net sales growth in fiscal 2022, following on from 20% organic net sales growth in the prior year.